SES posted €870 million in revenue for Q3 and an adjusted EBITDA of €413 million, driven by lower operating costs and contract restructuring revenue. The company secured €5.8 billion in new business and renewals in the first nine months, increasing its backlog to €10 billion. Reduced investment needs for IRIS² and progress on US C-band clearance add potential shareholder value. SES raised its 2026 EBITDA forecast to €1.5 billion, reflecting strong future earnings potential and supporting a Strong Buy rating.
SES S.A. and its Q3 performance provide context for readers. For those tracking Technology-sector US stocks on Pluang, 63 rose and 71 fell out of 150 priced stocks. Notable movers include CORZ at USD 14.04 with a 2.36% decline and GPRO at USD 0.69 with a 2.22% gain. Data is as of Nov 13, 2026 16:21 WIB.
The Philippines solar energy market is projected to grow from 5.43 GW in 2026 to 23.35 GW by 2032, with a CAGR of 27.46%. Growth is fueled by declining costs of solar panels and installation, government-backed renewable energy auctions, and increasin...
Equinor ASA shares will trade ex-dividend on the Oslo Stock Exchange starting November 13, 2026, for the second quarter of 2026. The declared dividend amount is $0.39 per share, payable in USD. This means investors buying shares from this date will n...
China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 suppliers from eight countries at the 9th China International Import Expo in Shanghai. The deals cover aircraft engines, aviation materials, jet fuel, and in-flight ca...
Eramet announced a €500 million share capital increase through a rights issue, offering 6 new shares for every 5 existing shares at €14.49 each. The proceeds will be used to reduce the company's debt and strengthen its balance sheet as part of a prev...
Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstra...
